← Leaderboards
Hedy L Kindler
University Of Chicago
$4,173,779
Attributed
$9,579,414
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $786K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,579,414 · 7
By mechanism
U10$4,563,167 · 2
UG1$3,723,627 · 1
P30$915,100 · 2
R21$377,520 · 1
M01$0 · 1
Top collaborators
- Steven J Chmura12 shared
- Mitchell C Posner12 shared
- Seiko D Yamada12 shared
- Ravi Salgia2 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Michelle M Le Beau$39,023,275
- James J. Dignam$36,155,075
- Gini F Fleming$2,647,078
- Greg Yothers$25,122,895
- Steven J Chmura$1,738,959
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsMemberChicagoUniversitiesMalignant NeoplasmsMentorsComprehensive Cancer CenterCancer Center Support GrantStatisticsEnsureProtocols DocumentationOncologyCancer Clinical TrialBasic ScienceProgramsDesignSurgical OncologyResourcesLaboratoriesClinical ProtocolsMedicineInstitutionCorrelative StudyFaculty
Grant awards (32)
UG1 - NCTN (Network Lead)$506,534
UG1 · FY2025 · CA · contact PI
Protocol Review and Monitoring System$213,098
P30 · FY2025 · CA · contact PI
UG1 - NCTN (Network Lead)$506,534
UG1 · FY2024 · CA · contact PI
Protocol Review and Monitoring System$105,819
P30 · FY2024 · CA · contact PI
UG1 - NCTN (Network Lead)$533,194
UG1 · FY2023 · CA · contact PI
UG1 - NCTN (Network Lead)$533,194
UG1 · FY2022 · CA · contact PI
Protocol Review and Monitoring System$116,376
P30 · FY2022 · CA · contact PI
UG1 - NCTN (Network Lead)$608,192
UG1 · FY2021 · CA · contact PI
Protocol Review and Monitoring System$117,056
P30 · FY2021 · CA · contact PI
UG1 - NCTN (Network Lead)$530,761
UG1 · FY2020 · CA · contact PI
Protocol Review and Monitoring System$117,056
P30 · FY2020 · CA · contact PI
Protocol Review and Monitoring System$4,734
P30 · FY2020 · CA · contact PI
UG1 - NCTN (Network Lead)$505,218
UG1 · FY2019 · CA · contact PI
Protocol Review and Monitoring System$117,056
P30 · FY2019 · CA · contact PI
NCI National Clinical Trials Network-Network Lead Academic Participating Sites$634,699
U10 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$118,559
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$2,726
P30 · FY2018 · CA · contact PI
Protocol Review and Monitoring System$2,620
P30 · FY2018 · CA · contact PI
NCI National Clinical Trials Network-Network Lead Academic Participating Sites$634,404
U10 · FY2017 · CA · contact PI
NCI National Clinical Trials Network-Network Lead Academic Participating Sites$542,404
U10 · FY2016 · CA · contact PI
NCI National Clinical Trials Network-Network Lead Academic Participating Sites$634,750
U10 · FY2015 · CA · contact PI
NCI National Clinical Trials Network-Network Lead Academic Participating Sites$785,950
U10 · FY2014 · CA · contact PI
Cancer and Leukemia Group B$237,055
U10 · FY2013 · CA · contact PI
Cancer and Leukemia Group B$258,606
U10 · FY2012 · CA · contact PI
Cancer and Leukemia Group B$244,995
U10 · FY2011 · CA · contact PI
Cancer and Leukemia Group B$266,604
U10 · FY2010 · CA · contact PI
Novel Targeted Therapy in Pancreatic Cancer$205,920
R21 · FY2010 · CA
Cancer and Leukemia Group B$323,700
U10 · FY2009 · CA · contact PI
Novel Targeted Therapy in Pancreatic Cancer$171,600
R21 · FY2009 · CA
PHASE I STUDY OF ORAL CEP-701 IN PATIENTS WITH SOLID TUMORS$0
M01 · FY2002 · RR
PHASE I STUDY OF ORAL CEP-701 IN PATIENTS WITH SOLID TUMORS$0
M01 · FY2000 · RR
PHASE I STUDY OF ORAL CEP-701 IN PATIENTS WITH SOLID TUMORS$0
M01 · FY2000 · RR